论文部分内容阅读
近年文献报道用胎肝细胞悬液输注疗法(简称FLCT)治疗再生障碍性贫血(以下称再障)取得了肯定的疗效。我们于1986年6月至12月采用多次FLCT治疗慢性再障3例共15例次,现初步小结如下。临床资料病例选择:3例患者符合1981年全国再障座谈会慢性再障诊断标准。均系男性,年龄分别为5、22、26岁,治疗前血红蛋白34～68克/L,红细胞1.15～2.0×10~(12)/L,白细胞1.9～3.6×10~9/L,血小板2～28×10~9/L。骨髓象均示增生低下。其病程分别为6、12、60月。临床上有明显贫血症状和体征。曾经丙睾、强的松、中药等治疗无效。胎肝细胞悬液制备方法:取胎龄4～5月
In recent years, it has been reported in the literature that fetal liver cell suspension infusion therapy (referred to as FLCT) for the treatment of aplastic anemia (hereinafter referred to as aplastic anemia) achieved a positive effect. We in June 1986 to December using multiple FLCT treatment of chronic aplastic anemia in 3 cases a total of 15 cases, the initial summary is as follows. Clinical data Case selection: 3 patients in line with the 1981 national aplastic anemia symposium chronic aplastic anemia diagnostic criteria. Were all male, with an average age of 5,22,26 years. Pretreatment hemoglobin 34 to 68 g / L, erythrocytes 1.15 to 2.0 × 10 12 / L, leukocytes 1.9 to 3.6 × 10 9 / L, platelet 2 ~ 28 × 10 ~ 9 / L. Bone marrow showed hyperplasia low. Their duration was 6, 12, 60 months. Obvious clinical symptoms and signs of anemia. Once the testis, prednisone, Chinese medicine and other treatment is invalid. Fetal liver cell suspension preparation method: take gestational age 4 to May